专题：Gastric Cancer Management and Outcomes

This cluster of papers represents a comprehensive exploration of gastric cancer, covering topics such as chemotherapy, endoscopic resection, molecular characterization, lymph node dissection, adjuvant and neoadjuvant therapy, clinical practice guidelines, metastatic gastric cancer, and survival analysis.
最新文献
TACE-HAIC versus HAIC combined with TKIs and ICIs for hepatocellular carcinoma with a high tumor burden—a propensity-score matching comparative study

article Full Text OpenAlex

High-fat Diet-associated Digestive Cancers: Mechanisms, Natural Product-based Therapies, and Drug Development

article Full Text OpenAlex

LBA81 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: A randomised, phase III study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric / gastroesophageal junction (G / GEJ) adenocarcinoma

article Full Text OpenAlex

Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy

article Full Text OpenAlex

Burden, trends, driving factors, and predictions of gastric cancer: a cross-national comparative analysis of China, Japan, and South Korea

article Full Text OpenAlex

Development and Validation of a New Prediction Criteria for Neoadjuvant Chemotherapy Response in Locally Advanced Gastric Cancer Based on Ferroptosis‐Related Biomarkers

article Full Text OpenAlex

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update

review Full Text OpenAlex

MA08.04 Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations

article Full Text OpenAlex

PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

article Full Text OpenAlex

PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC

article Full Text OpenAlex

近5年高被引文献
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

article Full Text OpenAlex 1622 FWCI237.5592

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

article Full Text OpenAlex 1239 FWCI177.5235

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

article Full Text OpenAlex 1226 FWCI250.4679

Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)

article Full Text OpenAlex 1091 FWCI151.5333

Helicobacter pylori infection

review Full Text OpenAlex 1021 FWCI267.1534

Gastric cancer treatment: recent progress and future perspectives

review Full Text OpenAlex 825 FWCI217.958

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

article Full Text OpenAlex 722 FWCI104.2762

Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death

article Full Text OpenAlex 707 FWCI70.9456

The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling study

article Full Text OpenAlex 688 FWCI142.791

Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention

review Full Text OpenAlex 676 FWCI219.2254